High vaccine effectiveness against severe COVID-19 outcomes and population preventable fraction during the Omicron era in Luxembourg: A nationwide retrospective risk factor analysis

被引:1
|
作者
Bejko, Dritan [1 ,6 ]
Ernst, Corinna [1 ]
Vergison, Anne [1 ]
Stranges, Saverio [2 ,3 ,4 ,5 ]
Zeegers, Maurice P. [6 ]
Mossong, Joel [1 ]
机构
[1] Hlth Directorate, Hlth Inspectorate, Luxembourg, Luxembourg
[2] Western Univ, Dept Epidemiol & Biostat, London, ON, Canada
[3] Western Univ, Dept Family Med, London, ON, Canada
[4] Western Univ, Dept Med, London, ON, Canada
[5] Univ Naples Federico II, Dept Clin Med & Surg, Naples, Italy
[6] Maastricht Univ, Sch Nutr & Translat Res Metab, Dept Epidemiol, Maastricht, Netherlands
关键词
Vaccine effectiveness; Natural immunity; COVID-19; Retrospective cohort; Hospital admission; Mortality;
D O I
10.1016/j.vaccine.2024.05.059
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Luxembourg experienced major consecutive SARS-CoV-2 infection waves due to Omicron variants during 2022 while having achieved a high vaccination coverage in 2021. We investigated the risk factors associated to severe outcomes (i.e., hospitalisation, deaths) and estimated vaccine effectiveness (VE) as well as the role of immunity conferred by prior infections against severe outcomes in adults. Methods: We linked reported SARS-CoV-2 cases among residents aged >= 20 years with vaccination data and SARS-CoV-2 related hospitalisations and deaths. Cases were followed-up until day 14 for COVID-19 related hospital admission and up to day 28 for mortality after a positive test. We analysed the association between the vaccination status and severe forms using proportional Cox regression, adjusting for previous infection, age, sex and nursing homes residency. VE was measured as 1-adjusted hazard ratio of vaccinated vs unvaccinated individuals. The population preventable fraction was computed using the adjusted hazard ratio and the proportion of cases within the vaccination category. Results: Between December 2021, and March 2023, we recorded 187143 SARS-CoV-2 cases, 1 728 (0.93%) hospitalizations and 611 (0.33%) deaths. The risk of severe outcomes increased with age, was higher among men and nursing home residents. Compared to unvaccinated adults, VE against hospitalization was 38.8% (95%CI: 28.1%-47.8%) for a complete primary cycle of vaccination, 62.1% (95%CI: 57.0%-66.7%) for one booster, and 71.6% (95%CI: 66.7%-76.2%) for two booster doses. VE against death was respectively 49.5% (95%CI: 30.8%63.3%), 69.0% (95%CI: 61.2%-75.3%) and 76.2% (95%CI: 68.4%-82.2%). Previous infection was not associated with lower risk of hospitalisation or mortality. The vaccination lowered mortality by 55.8 % (95%CI: 46.3%62.8%) and reduced hospital admissions by 49.1% (95%CI: 43.4%-54.4%). Conclusions: Complete vaccination and booster but not previous infection were protective against hospitalization and death. The vaccination program in Luxembourg led to substantial reductions in SARS-CoV-2-related mortality and hospitalizations at the population level.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Author Correction: Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes
    Ramandip Grewal
    Lena Nguyen
    Sarah A. Buchan
    Sarah E. Wilson
    Sharifa Nasreen
    Peter C. Austin
    Kevin A. Brown
    Deshayne B. Fell
    Jonathan B. Gubbay
    Kevin L. Schwartz
    Mina Tadrous
    Kumanan Wilson
    Jeffrey C. Kwong
    Nature Communications, 14
  • [2] COVID-19 VACCINE EFFECTIVENESS AGAINST OMICRON VARIANT IN PEDIATRIC GALICIAN POPULATION
    Mallah, N.
    Ares-Gomez, S.
    Pardo-Seco, J.
    Otero-Barros, M. T.
    Duran-Parrondo, C.
    Nartallo-Penas, V.
    Miras-Carballal, S.
    Rivero-Calle, I.
    Martinon-Torres, F.
    GACETA SANITARIA, 2023, 37 : S172 - S172
  • [3] High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of Omicron
    Baum, Ulrike
    Poukka, Eero
    Leino, Tuija
    Kilpi, Terhi
    Nohynek, Hanna
    Palmu, Arto A.
    BMC INFECTIOUS DISEASES, 2022, 22 (01)
  • [4] High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of Omicron
    Ulrike Baum
    Eero Poukka
    Tuija Leino
    Terhi Kilpi
    Hanna Nohynek
    Arto A. Palmu
    BMC Infectious Diseases, 22
  • [5] COVID-19 Vaccine Effectiveness Studies against Symptomatic and Severe Outcomes during the Omicron Period in Four Countries in the Eastern Mediterranean Region
    Runge, Manuela
    Karimian, Zahra
    Kheirandish, Mehrnaz
    Borghi, Giulio
    Wodniak, Natalie
    Fahmy, Kamal
    Mantel, Carsten
    Cherian, Thomas
    Said, Zeinab Nabil Ahmed
    Najafi, Farid
    Thneibat, Fatima
    Ul-Haq, Zia
    Fazid, Sheraz
    Salama, Iman Ibrahim
    Shadmani, Fatemeh Khosravi
    Alrawashdeh, Ahmad
    Sirous, Shadrokh
    Bellizzi, Saverio
    Ahmed, Amira
    Lukwiya, Michael
    Rashidian, Arash
    VACCINES, 2024, 12 (08)
  • [6] Vaccine effectiveness against severe COVID-19 during the Omicron wave in Germany: results from the COViK study
    Anna Stoliaroff-Pepin
    Caroline Peine
    Tim Herath
    Johannes Lachmann
    Wiebke Hellenbrand
    Delphine Perriat
    Achim Dörre
    Andreas Nitsche
    Janine Michel
    Marica Grossegesse
    Natalie Hofmann
    Thomas Rinner
    Claudia Kohl
    Annika Brinkmann
    Tanja Meyer
    Daniel Stern
    Fridolin Treindl
    Brigitte G. Dorner
    Sascha Hein
    Laura Werel
    Eberhard Hildt
    Sven Gläser
    Helmut Schühlen
    Caroline Isner
    Alexander Peric
    Ammar Ghouzi
    Annette Reichardt
    Matthias Janneck
    Guntram Lock
    Dominik Huster
    Thomas Grünewald
    Lars Schaade
    Ole Wichmann
    Thomas Harder
    Infection, 2023, 51 : 1093 - 1102
  • [7] Vaccine effectiveness against severe COVID-19 during the Omicron wave in Germany: results from the COViK study
    Stoliaroff-Pepin, Anna
    Peine, Caroline
    Herath, Tim
    Lachmann, Johannes
    Hellenbrand, Wiebke
    Perriat, Delphine
    Doerre, Achim
    Nitsche, Andreas
    Michel, Janine
    Grossegesse, Marica
    Hofmann, Natalie
    Rinner, Thomas
    Kohl, Claudia
    Brinkmann, Annika
    Meyer, Tanja
    Stern, Daniel
    Treindl, Fridolin
    Dorner, Brigitte G.
    Hein, Sascha
    Werel, Laura
    Hildt, Eberhard
    Glaeser, Sven
    Schuehlen, Helmut
    Isner, Caroline
    Peric, Alexander
    Ghouzi, Ammar
    Reichardt, Annette
    Janneck, Matthias
    Lock, Guntram
    Huster, Dominik
    Gruenewald, Thomas
    Schaade, Lars
    Wichmann, Ole
    Harder, Thomas
    INFECTION, 2023, 51 (04) : 1093 - 1102
  • [8] Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes (vol 14, 1273 , 2023)
    Grewal, Ramandip
    Nguyen, Lena
    Buchan, Sarah A.
    Wilson, Sarah E.
    Nasreen, Sharifa
    Austin, Peter C.
    Brown, Kevin A.
    Fell, Deshayne B.
    Gubbay, Jonathan B.
    Schwartz, Kevin L.
    Tadrous, Mina
    Wilson, Kumanan
    Kwong, Jeffrey C.
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [9] Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes (vol 14, 1273, 2023)
    Grewal, Ramandip
    Nguyen, Lena
    Buchan, Sarah A.
    Wilson, Sarah E.
    Nasreen, Sharifa
    Austin, Peter C.
    Brown, Kevin A.
    Fell, Deshayne B.
    Gubbay, Jonathan B.
    Schwartz, Kevin L.
    Tadrous, Mina
    Wilson, Kumanan
    Kwong, Jeffrey C.
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [10] Waning vaccine response to severe COVID-19 outcomes during omicron predominance in Thailand
    Intawong, Kannikar
    Chariyalertsak, Suwat
    Chalom, Kittipan
    Wonghirundecha, Thanachol
    Kowatcharakul, Woravut
    Thongprachum, Aksara
    Chotirosniramit, Narain
    Noppakun, Kajohnsak
    Khwanngern, Krit
    Teacharak, Worachet
    Piamanant, Prapon
    Chantaklang, Pannawich
    Khammawan, Pimpinan
    PLOS ONE, 2023, 18 (05):